Gastroenteropancreatic neuroendocrine neoplasms
Conditions
Interventions
Induction of everolimus at a dose of 10 mg once daily after TAE using with embosphere which contain embolic beads
Sponsors
Takeuchi Yasuto
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Patients who diagnosed with non-functionnal GEP-NEN of which grade was G1 confirmed pathologically 2 Patients with liver metastatic tumors who have no treatment history of TAE and chemotherapy 3 20 age old over 4 Patienst who have been fully informed consent 5 Regardless of gender 6 Less than 1 of performance status 7 Adequate hematologic and end-organ function
Exclusion criteria
Exclusion criteria: 1 Tumor thrombus or thrombus in the main and/or first portal vein 2 Moderate or severe ascites 3 Severe arteriovenous shunt in the liver 4 Allergy for contrast media 5 Less than 30 mL/min of eGFR 6 Allergy for Everolimus, Sirolimus and Sirolimus derivatives 7 Allergy for gelatin 8 Prior treatment with mTOR inhibitor 9 Long treatment with corticosteroids or other immunostimulatory agents 10 Significant cardiovascular, infectious, diabate or plumonary disease 11 The participant has a fasting glycemic level of 1.5 ULN or higher at the start of the screening period 12 Patients who diagnosed as Interstitial pneumonia by CT 13 Being pregnant or possibly pregnant 14 Patients who judged as not suitable for chemotherapy 15 Patients who judged as inappropriate candidate by the chief medical examine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 Overall Survival 2 Response Rate 3 Disease Control Rate 4 Adverse Event | — |
Contacts
Public ContactNozomu Wada
Okayama University Hospital
Outcome results
None listed